T1	Participants 69 100	advanced, life-limiting illness
T2	Participants 389 426	patients with limited life expectancy
T3	Participants 528 567	patients in the palliative care setting
T4	Participants 603 678	This was a multicenter, parallel-group, unblinded, pragmatic clinical trial
T5	Participants 680 958	Eligibility included adults with an estimated life expectancy of between 1 month and 1 year, statin therapy for 3 months or more for primary or secondary prevention of cardiovascular disease, recent deterioration in functional status, and no recent active cardiovascular disease
T6	Participants 1616 1751	A total of 381 patients were enrolled; 189 of these were randomized to discontinue statins, and 192 were randomized to continue therapy
